EU/3/19/2211

Table of contents

About

On 17 October 2019, orphan designation EU/3/19/2211 was granted by the European Commission to Therapharm Deutschland GmbH, Germany, for besilesomab for treatment in haematopoietic stem cell transplantation.

Key facts

Active substance
besilesomab
Disease / condition
Treatment in haematopoietic stem cell transplantation
Date of first decision
17/10/2019
Outcome
Positive
EU designation number
EU/3/19/2211

Sponsor's contact details

Therapharm Deutschland GmbH
Eichthalstrasse 12 A
82377 Penzberg
Germany
Tel: +49 160 91762637
E-mail: klaus.bossletkb@gmail.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

How useful was this page?

Add your rating